Varenicline

被引:0
|
作者
Raymond Niaura
Carole Jones
Peter Kirkpatrick
机构
[1] Butler Hospital,the Department of Psychiatry and Human Behavior
[2] IMS Health,undefined
[3] Nature Reviews Drug Discovery,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Varenicline tartrate (Chantix; Pfizer), an α4β2 nicotinic receptor partial agonist, was approved by the US FDA as an aid to smoking cessation treatment in May 2006.
引用
收藏
页码:537 / 538
页数:1
相关论文
共 50 条
  • [31] Varenicline: Implications for the Field
    Bobak, Alex
    JOURNAL OF SMOKING CESSATION, 2007, 2 : 8 - 11
  • [34] Varenicline and Suicide: Reconsidered and Reconciled
    Niaura, Ray
    NICOTINE & TOBACCO RESEARCH, 2016, 18 (01) : 1 - 1
  • [35] Acute Worsening of Tics on Varenicline
    Mittal, Shivam Om
    Klassen, Bryan T.
    Hassan, Anhar
    Bower, James H.
    Coon, Elizabeth A.
    CLINICAL NEUROPHARMACOLOGY, 2017, 40 (05) : 231 - 232
  • [36] Varenicline for Maintenance of Smoking Cessation
    不详
    CURRENT CARDIOVASCULAR RISK REPORTS, 2007, 1 (05) : 357 - 358
  • [38] Varenicline (Chantix) for tobacco dependence
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2006, 48 (1241-2): : 66 - 68
  • [39] Varenicline (Chantix) for smoking cessation
    Love, Bryan L.
    Merz, Tonja
    AMERICAN FAMILY PHYSICIAN, 2007, 76 (02) : 279 - 280
  • [40] AN OVERVIEW ON ANALYTICAL PROFILE OF VARENICLINE
    Mahajan, Vikas G.
    Khadse, Saurabh C.
    Chalikwar, Shailesh S.
    Chaudhari, Dhanashri A.
    Hadole, Sneha R.
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (04): : 8580 - 8588